Report Categories
View AllRecent Articles
View All
IPDN Professional shares sink 946 after posting negative Q2 2023 EPS with no analyst consensus estimates
CYN Cyngn falls 457 after Q3 2025 EPS misses analyst estimates by 188 percent
iShares Russell 2000 ETF IWM Geopolitical and Energy Risk Disconnect Amid Strong SmallCap Rally
NVT nVent delivers narrow Q4 2025 EPS miss sending share price down 067 percent in todays trading
Renewed RussiaUkraine Conflict Escalation Raises Market Uncertainty
NVIDIAs Market Cap Surpasses Germanys GDP as Big Tech Dominance Grows
Googles AI Chip Expansion May Pressure Nvidia and Cloud Rivals CoreWeave and Nebius
ICRA Flags Sharp Decline in IBC Recovery Rates to 22 in H2 FY26
Mortgage Rates Edge Up to 653 Adding Pressure on Spring Homebuyer Demand
Stellantis Turnaround Strategy Prediction Market Crackdown and Oura IPO Lead Morning Market News
NCS Multistage Holdings Inc NCSM Q1 2026 Earnings EPS Misses Estimates Significantly Revenue Data Unavailable
ALZN Q1 2026 Earnings Narrowing Losses Beat Estimates by 70
ITT Inc Q1 2026 Earnings Strong EPS Beat Drives Positive Market Response
IIIN Q1 2026 Earnings EPS Misses Estimates as Steel Wire Demand Softens Stock Gains Despite Shortfall
SEDG Q1 2026 Earnings EPS Miss by 50 Solar Market Headwinds Persist
MBC Q1 2026 Earnings EPS Surges 69 Above Estimates Shares Jump 127
LifeMD LFMD Slips 066 as Stock Hovers Near Established Support Level
John Hancock Preferred Income Fund III HPS Edges Higher Amid Modest Trading Activity
MITN Slips 05 Amid FixedIncome Volatility Technical Levels Hold
Xsolla SPAC 1 Units XSLLU Holds Steady at 998 Neutral Stance Ahead of Catalysts
JELDWEN Holding Inc JELD Stages a Modest Recovery Navigating Support and Resistance Levels
JNJ Q1 2026 Earnings Slight EPS Beat Amidst Operational Strength
NTRB Q1 2026 Earnings Massive EPS Beat Highlights Cost Control Amid PreRevenue Stage
RWAYI Q1 2026 Earnings EPS Miss Amidst Narrowed Lending Margins
BHFAM Q1 2026 Earnings EPS Misses Estimates Amid Challenging Market Conditions
Verrica Pharmaceuticals VRCA Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Sees Modest Stock Gain